Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-world evidence for nucleoside/nucleotide analogues in a 5-year multicentre study of antiviral-naive chronic hepatitis B patients in China: 52-week results.

Antiviral therapy - 1 Jan 2018

Jia Jidong, Tang Hong, Ning Qin, Jiang Jiaji, Dou Xiaoguang, Zhang Mingxiang, Zhang Shuqin, Shang Jia, Lu Wei, Ye Yinong, Wang Xin, Li Mingshu, Liu Jie, Bo Qingyan, Tan Wenzhong

Abstract excerpt

BACKGROUND: In China, the clinical management of chronic hepatitis B (CHB) is complicated by the use of variousnucleoside/nucleotide analogue (NUC) regimens in treatment-naive patients, including NUCs with low genetic barriers to resistance, with/without add-on therapy and de novo NUC combinations. This longitudinal observational study therefore investigated the real-world clinical management and efficacy of NUC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Substitution
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B, Chronic

Share to Hepatitis B virus

Share to Kaplan-Meier Estimate

Share to Liver Function Tests

Share to Nucleotides

Share to Viral Load

Source

Identifiers

PMID: 29116050
DOI: 10.3851/IMP3205

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world evidence for nucleoside/nucleotide analogues in a 5-year multicentre study of antiviral-naive chronic hepatitis B patients in China: 52-week results.PMID 29116050Read ↗

Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study.Semantic proximity Read ↗

Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients.Semantic proximity Read ↗

Current developments in nucleoside/nucleotide analogues for hepatitis B.Semantic proximity Read ↗

Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection.Semantic proximity Read ↗

Chronic hepatitis B therapy: available drugs and treatment guidelines.Semantic proximity Read ↗

Evaluation of genotype characteristics and drug resistance mutations in patients with chronic hepatitis B.Semantic proximity Read ↗

Hepatitis B: treatment choice and monitoring for response and resistance.Semantic proximity Read ↗

Current treatment status and barriers for patients with chronic HCV infection in mainland China: A national multicenter cross-sectional survey in 56 hospitals.Semantic proximity Read ↗

Efficacy of Different Nucleoside Analog Rescue Therapies for Entecavir-Resistant Chronic Hepatitis B PatientsSemantic proximity Read ↗

Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience.Semantic proximity Read ↗

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study.Semantic proximity Read ↗

Evaluation of genotype characteristics and drug resistance mutations in patients with chronic hepatitis BSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.